Cellmid Share Price
A$0.215
0.0 0.0%
market vs.
industry Growth & Value
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 7.68 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.21 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry Quality
| Year End 30th Jun | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg | |
| Revenue | A$m | ||||||||||
| Operating Profit | A$m | ||||||||||
| Net Profit | A$m | ||||||||||
| EPS Reported | AUD¢ | ||||||||||
| EPS Normalised | AUD¢ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | AUD¢ | ||||||||||
| Capex ps | AUD¢ | ||||||||||
| Free Cashflow ps | AUD¢ | ||||||||||
| Dividends | |||||||||||
| Dividend ps | AUD¢ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | A$m | ||||||||||
| Working Capital | A$m | ||||||||||
| Net Fixed Assets | A$m | ||||||||||
| Net Debt | A$m | ||||||||||
| Book Value | A$m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | AUD¢ | -27.6% | |||||||||
| Leverage (ttm) | Total | -Intang | +Pension | ||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % |
| Liquidity (ttm) | ||
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | |
| Asset Turnover | |
| Rec's Turnover | |
| Stock Turnover | |
market vs.
industry Recent History
| Latest interim period (ended 31st Dec '18) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Compound Annual Growth Rate | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
Broker Consensus Trend
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 1 | 0 |
Cellmid Limited develops and markets therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The Company operates in two segments: research and development of diagnostics and therapeutics, and research, development and marketing of hair growth products. It develops and commercializes diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine (Midkine Businesses, Lyramid and Kinera), and the development and sale of over-the-counter (OTC) treatments to alleviate excessive and abnormal hair loss, and re-establish the natural hair growth cycle (Consumer Health Business). Its products include Midkine ELISA kit; Advangen International hair loss products, and Evolis products, which are a range of hair growth products. The Company, through its subsidiaries, develops and sells treatments for various forms of hair loss (alopecia).
Directors: Maria Halasz (CEO) , Lee Tamplin (SEC) , David King (NEC) , Martin Cross (NED) , Dennis Eck (NED) 73, Bruce Gordon (NED) , Edward Walton (NED) ,
No. of Employees: n/a No. of Shareholders: n/a
| Last Annual | June 30th, 2018 |
| Last Interim | December 31st, 2018 |
| Incorporated | October 8, 2004 |
| Public Since | December 9, 2005 |
| Shares in Issue | 84,108,592 |
| Free Float | 65.6m (78.0%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange |
Australian Stock Exchange - SEATS
|
| Eligible for | an ISA? a SIPP? |
| Address | SE 204 L 2 55 Clarence Street, SYDNEY, 2000, Australia |
| Web | http://www.cellmid.com.au/ |
| Phone | +61 2 92216830 |
| Contact | () |
| Auditors | Grant Thornton |
Recent ↓
Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.
